Skip to main content
. Author manuscript; available in PMC: 2016 Jan 21.
Published in final edited form as: Neuron. 2014 Dec 31;85(2):303–315. doi: 10.1016/j.neuron.2014.12.019

Figure 7. Intrastriatal Rhes overexpression improves disease phenotypes in N171-82Q mice.

Figure 7

(A) RT-qPCR analysis of endogenous Rhes levels from striatal lysates of unaffected individuals (Ctl, N=4) and HD patients (N=10), and 6-week-old N171-82Q (N=5) and WT (N=4) littermates. Data represent mean ± SEM. *P<0.05, ***P<0.001, Student's t-test. (B) Rotarod assessment of N171-82Q and WT mice after bilateral injection of AAV.Rhes, AAV.RhesS33N, or saline into the striatum at 7 weeks of age (N=10-14 mice per group at 14 weeks of age; N=6-13 mice per group at 18 weeks of age). Rotarod data from three consecutive days at 14 and 18 weeks of age are shown as latency to fall. Saline and AAV.RhesS33N-injected N171-82Q mice performed significantly worse compared to AAV.Rhes-injected N171-82Q mice on the rotarod at 14 and 18 weeks of age. NS=Not statistically significant. Data represent mean ± SEM. *P<0.05; **P<0.01; ***P<0.001, One-way ANOVA with Tukey's post-hoc test. (C) DARPP-32 staining and quantification of MSN area of N171-82Q mice striatal tissue sections after unilateral injection of AAV.Rhes and contralateral injection of AAV.GFP at 7 weeks of age. Tissues were harvested at 19 weeks of age (N=3 mice/group; GFP=245 cells; Rhes=251 cells). Data represent mean ± SEM. ***P<0.001, Student's t-test. Scale bars: 50 μm. (D) qPCR analysis of PGC-1α in striata from AAV.Rhes-or saline-treated N171-82Q and WT mice (n=6-9 per group) harvested at the end of the study (19 weeks of age). C=Control. *P<0.05, Student's t-test.